Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interview: EU Or US? Deciding On The Best Market Entry Point Amid Evolving Clinical Requirements

Executive Summary

The timescale for CE-marking devices that require clinical studies may stretch to at least double the timescale for US 510(k) clearance as the EU landscape evolves, according to consultant Maria Donawa. In a Q&A with Medtech Insight, she assesses the ongoing changes and whether the clinical data requirement scales are tipping to such an extent that the US will increasingly be a favored point-of-market entry.

You may also be interested in...

TCT 2016: Cardiologists Urge More Alignment Between EU And US Regs

More robust oversight of medical devices in the EU is coming, and some European cardiologists speaking at the Transcatheter Cardiovascular Therapeutics annual meeting in Washington, DC, said that is a good thing despite the device industry’s history of praising the EU system for supporting innovation. They also pushed for more harmonization between the EU and US systems. Watch a video report from an FDA Town Hall panel at TCT on the topic and read our report from the meeting.

Companies Fear EU Clinical Evaluation Guidance Document Is Becoming De Facto Law

Are EU notified bodies raising the bar too high when it comes to assessing manufacturer compliance against the current Medical Devices Directive and Active Implantable Medical Devices Directive? Industry says it is challenged by notified bodies’ use of the latest EU clinical evaluation guidance document.

Medtech Biggest Casualty In Swiss/EU Uncertainty As Worst-Case Scenario Looms

Eighteen years of free trade threatens to come to a sudden stop, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts